Price Performance of Celldex Therapeutics, Inc. (CLDX)
When it comes to price performance, Celldex Therapeutics, Inc. (NASDAQ:CLDX) has had quite a year. This company’s shares managed to reach their 1-Year High point, which was $37.35 on 03/27/18, compared to when it go to its cheapest point in the past 12 months, which was $2.74 on 12/26/18.
At the end of the most recent trading day, Celldex Therapeutics, Inc. closed at $4.94. The stock began the trading session at $5.13 and hit a high of $5.21. The lowest price during the trading day was $4.85.
The shares of this company, which operates in the healthcare sector, reached a trading volume of about 386,608 throughout the day, which was clearly lower than the average daily volume for these shares.
At the time of writing, this publicly-traded organization holds a total market value of 61.75M, with 137 employees on its payroll.
Moving ahead, if we take a look at what all stock market pros are currently saying about Celldex Therapeutics, Inc. (NASDAQ:CLDX), the mean rating for this stock is 2.00. How is that calculated? Well, 0 analysts have given this company a BUY rating, 1 is rated it as OUTPERFORM, 0 have recommended that investors HOLD, 0 are considering it an UNDERPERFORM and 0 have recommended that owners of these shares SELL.
A month ago, 0 analysts thought this stock was a BUY, 1 of them posted an OUTPERFORM rating, 0 analysts recommended to HOLD this stock, 0 of them provided an underperform rating and 0 rated it as a Sell.
This company’s 100-day moving average was 4.86, while its price change was posted at -0.46. Similarly, Celldex Therapeutics, Inc. (NASDAQ:CLDX) experienced a 100-day Percent movement of -8.52% with a trading volume reaching 282,042.
Continuing to look at similarly important data, this stock’s distance from its 200-day Simple Moving Average, or SMA 200, is -18.13% at the time of writing. This organization’s revenue over the trailing twelve months (TTM) of active operations is 9.50M, considering the fact that it was able to rack up the income of -$151.20M through that period of time.
By dividing a company’s current total liabilities by its stockholders’ equity, we find the company’s Total Debt to Equity Ratio (also known as D/E ratio), a solid method of understanding a company’s financial power. This metric just illustrates how much debt an organization is using to support its assets in relation to how much its shareholder’s equity is worth. CLDX’s Total Dept/Eq ratio is sitting at 0.00 at the time of writing, while its long-term Dept/Eq ratio is 0.00
While maintaining our attention on the Technical analysis of Celldex Therapeutics, Inc. (NASDAQ:CLDX), during the last 50 days, its Raw Stochastic average was observed 15.91%, representing a downgrade from this organization’s 20-day Raw Stochastic average – which was posted 30.52%. During the last 20-days time span, this firm’s Stochastic %K was 31.43% and its Stochastic %D was noted 26.03%.
When glancing in-depth into the past price journey that Celldex Therapeutics, Inc. (NASDAQ:CLDX) stock has taken, we can observe multiple moving trends. This particular stock’s current year-to-date (YTD) price performance is standing at 66.41%. Meanwhile, during the past six months of trading, this stock has deteriorated to -20.85%, along with a full-year performance of -86.61%. This company’s shares increased nearly 5.36% during the last 7-day stretch and up 4.66% over the last 30 days.